Latest News

Shire’s lanadelumab and SHP647 meet endpoints in respective trials

Irish pharmaceutical company Shire has reported positive topline results from its Phase III HELP clinical trial of lanadelumab to treat hereditary angioedema (HAE) and from the Phase II...

Shire’s lanadelumab and SHP647 meet endpoints in respective trials

Albireo to initiate A4250’s Phase III clinical programme to treat PFIC

Albireo Pharma is planning to initiate a Phase III clinical programme of its product candidate A4250 in the second half of this year for the treatment of patients with progressive...

Albireo to initiate A4250’s Phase III clinical programme to treat PFIC

Myovant reports positive data from Phase II trial of relugolix in Japan for endometriosis

Myovant reports positive data from Phase II trial of relugolix in Japan for endometriosis

Aurinia begins voclosporin dosing in Phase III trial for LN

Canadian-based biopharmaceutical firm Aurinia Pharmaceuticals has begun dosing patients in the Phase III AURORA clinical trial of voclosporin to treat lupus nephritis...

Aurinia begins voclosporin dosing in Phase III trial for LN

Medical research funders and NGOs agree on new WHO clinical trial policies

Medical research funders and NGOs agree on new WHO clinical trial policies

Syndax’s entinostat advances into second stage of Phase II trial for NSCLC

US-based biopharmaceutical firm Syndax Pharmaceuticals’ entinostat has advanced into the second stage of Phase II of the ENCORE 601 clinical trial for the treatment of patients with non-small...

Syndax’s entinostat advances into second stage of Phase II trial for NSCLC

Interface Clinical Research develops new GP model to minimise clinical trial drop outs

Interface Clinical Services’ division Interface Clinical Research has developed a new model to decrease the number of patient dropouts from clinical...

Interface Clinical Research develops new GP model to minimise clinical trial drop outs

Capecitabine improves post-surgery survival period in bile duct cancer patients

Capecitabine improves post-surgery survival period in bile duct cancer patients

Actinogen begins enrolment in Phase II trial of Xanamem to treat Alzheimer’s disease

Australian-based biotech firm Actinogen Medical has begun patient enrolment and dosing in the Phase II XanADu clinical trial of Xanamem for the treatment of Alzheimer's disease....

Actinogen begins enrolment in Phase II trial of Xanamem to treat Alzheimer’s disease

Immunovaccine to study DPX-Survivac in Phase II combination trial for DLBCL

Immunovaccine to study DPX-Survivac in Phase II combination trial for DLBCL

Syros starts dosing in Phase I trial of SY-1365 to treat solid tumours

US-based biopharmaceutical company Syros Pharmaceuticals has started dosing patients in its Phase I clinical trial of SY-1365 for the treatment of patients with advanced solid...

Syros starts dosing in Phase I trial of SY-1365 to treat solid tumours

AstraZeneca’s Imfinzi meets primary endpoint in Phase III trial for stage III NSCLC

AstraZeneca’s Imfinzi meets primary endpoint in Phase III trial for stage III NSCLC

Glenmark Pharmaceuticals to investigate GBR 1342 in Phase I trial for multiple myeloma

Indian pharmaceutical firm Glenmark Pharmaceuticals has obtained clearance from the US Food and Drug Administration (FDA) for its investigational new drug (IND) application to commence a Phase...

Glenmark Pharmaceuticals to investigate GBR 1342 in Phase I trial for multiple myeloma

MMJ PhytoTech to initiate Phase II trial of PTL201 to treat MS symptoms

MMJ PhytoTech’s Israeli division PhytoTech Therapeutics has obtained approvals from Ministry of Health and the Sheba Hospital regulatory body Helsinki, to initiate a Phase II clinical trial of...

MMJ PhytoTech to initiate Phase II trial of PTL201 to treat MS symptoms

Mithra and Fuji Pharma to commence Estelle’s PK trial in ASEAN markets

Belgium-based Mithra Pharmaceuticals and Japan's Fuji Pharma are set to begin a pharmacokinetic (PK) ethnobridging trial of Estelle in Japanese and Caucasian...

Mithra and Fuji Pharma to commence Estelle’s PK trial in ASEAN markets

Peloton starts dosing in Phase II trial of PT2385 to treat VHL-associated kidney cancer

Peloton starts dosing in Phase II trial of PT2385 to treat VHL-associated kidney cancer

Lilly’s galcanezumab meets primary endpoint in three Phase III trials for migraine

US-based healthcare firm Eli Lilly and Company has reported positive results from three Phase III EVOLVE-1, EVOLVE-2 and REGAIN clinical trials of galcanezumab to prevent episodic and...

Lilly’s galcanezumab meets primary endpoint in three Phase III trials for migraine

Corium’s Corplex Donepezil demonstrates positive outcome in pilot BE trial

US-based Corium International has reported positive preliminary results from a pilot bioequivalence (BE) clinical trial of Corplex Donepezil in healthy...

Corium’s Corplex Donepezil demonstrates positive outcome in pilot BE trial

Sierra to amend two ongoing Phase I trials of SRA737 in UK

Canadian-based drug development firm Sierra Oncology has received clearance from UK regulatory authorities to amend two of its ongoing Phase I clinical trials of SRA737 within the...

Sierra to amend two ongoing Phase I trials of SRA737 in UK

Aimmune’s Phase III trial commences enrolment to study AR101 for peanut allergy

Aimmune’s Phase III trial commences enrolment to study AR101 for peanut allergy

DrugDev and Informa partner to enable easy site identification for clinical trials

DrugDev and Informa’s Pharma Intelligence vertical, Citeline, have integrated their respective platforms to allow easy and efficient identification of ideal sites for conducting clinical...

DrugDev and Informa partner to enable easy site identification for clinical trials
cachename:Newscachekey:rd-137342983_1031809799_rd-1665407042_1857678299_rd-488908060_1460672566_ap1460672566_1857678299_80855758